Fox Run Management L.L.C. Takes $118,000 Position in Kodiak Sciences Inc. (NASDAQ:KOD)

Fox Run Management L.L.C. purchased a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 11,841 shares of the company’s stock, valued at approximately $118,000.

Several other hedge funds have also recently bought and sold shares of KOD. Peapod Lane Capital LLC acquired a new stake in Kodiak Sciences in the fourth quarter valued at $1,660,000. FMR LLC grew its stake in Kodiak Sciences by 26.4% in the 3rd quarter. FMR LLC now owns 200,971 shares of the company’s stock valued at $525,000 after acquiring an additional 41,987 shares during the last quarter. Barclays PLC increased its holdings in Kodiak Sciences by 65.5% during the 3rd quarter. Barclays PLC now owns 79,658 shares of the company’s stock valued at $208,000 after acquiring an additional 31,527 shares in the last quarter. JPMorgan Chase & Co. raised its position in Kodiak Sciences by 220.9% during the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock worth $117,000 after acquiring an additional 30,735 shares during the last quarter. Finally, AlphaQuest LLC purchased a new stake in shares of Kodiak Sciences in the fourth quarter valued at about $256,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Kodiak Sciences Price Performance

Kodiak Sciences stock opened at $2.91 on Friday. The stock has a market capitalization of $153.14 million, a P/E ratio of -0.80 and a beta of 2.26. Kodiak Sciences Inc. has a 12-month low of $2.19 and a 12-month high of $11.60. The firm’s 50-day moving average is $4.85 and its two-hundred day moving average is $5.40.

Kodiak Sciences (NASDAQ:KOD) last announced its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.06. As a group, analysts forecast that Kodiak Sciences Inc. will post -3.45 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Monday, December 9th.

Kodiak Sciences Profile

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.